Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent~* patients have to be in a cognitive state that allows them to understand the rationale and necessity of study therapy and procedures.~* newly diagnosed histologically proven GBM or gliosarcoma WHO Grad IV~* methylated MGMT promoter in the tumor~* estimated life expectancy of at least 12 weeks~* Karnofsky Performance Score (KPS) ≥ 70%~* patient compliance and geographic proximity that allow adequate follow up~* male and female patients with reproductive potential must use an approved contraceptive method~* pre-menopausal female patients with childbearing potential: a negative serum pregnancy test must be obtained prior to treatment start~* Adequate organ function as described below:~Adequate bone marrow reserve:~white blood cell (WBC) count \> 3000/µl, granulocyte count \>1500/µl, platelets \> 100000/µl, haemoglobin ≥ 10 g/dl Adequate liver function bilirubin \< 1.5 times above upper limit of normal range (ULN), ALT and AST \< 3 times ULN creatinine \< 1.5 times ULN~Adequate blood clotting:~PT and PTT within normal limits Negative HIV test~Exclusion Criteria:~* prior malignancy~* prior chemotherapy~* prior radiotherapy to the brain~* concurrent administration of any other anti-tumor therapy~* allergy or other intolerability of temozolomide, CCNU, dacarbazine or other nitrosourea derivatives~* unable to undergo MRI~* past medical history of diseases with poor prognosis~* known HIV infection, active Hepatitis B or C infection~* any active infection~* female patients that are pregnant or breastfeeding~* patients with reproductive potential who do not accept to use contraception~* treatment in another clinical trial~* any psychological, cognitive, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up scheduled visits (at the discretion of investigator)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- lomustine (CCNU) + temozolomide (TMZ) and radiotherapy (Type: EXPERIMENTAL): 60 Gy standard radiotherapy (RT, 30 x 2 Gy) Six 42-day courses of oral CCNU 100 mg/m2 (day 1) and oral TMZ 100 mg/m2 (day 2-6), first CCNU application during the first week of RT CCNU/TMZ and radiotherapy start 2-5 weeks after diagnosis (day of surgery for glioblastoma (GBM)). In courses 2-6, TMZ dose are adjusted according to the hematotoxicity observed in the previous course and can be increased stepwise up to 200 mg/m2/day
- temozolomide and radiotherapy (Type: ACTIVE_COMPARATOR): 60 Gy standard radiotherapy (RT, 30 x 2 Gy) and concomitant TMZ therapy (daily TMZ 75 mg/m2) starting with the first day of radiotherapy Six 28-day courses of TMZ (day 1-5) starting 4 weeks after completion of radiotherapy. In the first course TMZ is given at a dose of 150 mg/m2/day, in case no toxicity is observed, the 2nd course is applied at a daily dose of 200 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).